Background The chlamydial proteins CT443 (OmcB) and CT521 (rl16) have previously been
identified as human B and/or T cell targets during a chlamydial infection in humans. Here we …

Chlamydia trachomatis is a major cause of sexually transmitted disease (STD) for which a
vaccine is needed. CD4+ T-helper type 1 (Th1) cell-mediated immunity is an important …

Defining the mechanisms of immunity conferred by the combination of antibody and CD4+ T
cells is fundamental to designing an efficacious chlamydial vaccine. Using the Chlamydia …

A vaccine against genital tract infections caused by Chlamydia trachomatis is urgently
needed. We have previously identified a number of immunodominant human T-and/or B-cell …

Despite several decades of intensive studies, no vaccines against Chlamydia trachomatis,
an intracellular pathogen causing serious ocular and urogenital diseases, are available yet …

To search for optimal immunization conditions for inducing protective immunity against
upper genital tract pathologies caused by chlamydial intravaginal infection, we compared …

To search for subunit vaccine candidates, immunogenic chlamydial antigens identified in
humans were evaluated for protection against both infection and pathology in a mouse …

Chlamydia trachomatis is the most common bacterial sexually transmitted disease in the
world and specifically in the United States, with the highest incidence in age-groups 14–19 …

There is currently no licensed vaccine against Chlamydia trachomatis, the leading cause of
sexually transmitted bacterial disease worldwide. Conventional vaccination attempts using …

Understanding the cellular populations and mechanisms responsible for overcoming
immune compartmentalization is valuable for designing vaccination strategies targeting …